Forecyte Bio opened its brand-new, state-of-the-art cell and gene therapy GMP facility in Shanghai, China, on March 31, following the opening of its U.S. facility in January. The 140,000 square foot facility, with a price tag of nearly $40 million, offers multiple GMP production lines for plasmids, viral vectors, and cell therapies. The dual sites in the U.S. and China offer advantages to cell and gene therapy (CGT) companies, especially those with the intention of filing internationally. ...